Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
• Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
• Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
• Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
• Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
• Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
• Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.

Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis

Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.

Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.

Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis

Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.

Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

• Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
• Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
• Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

• Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
• Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
• Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.